{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:33:35Z","timestamp":1787506415454,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality of life (QoL) of EoE patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The multicountry cross-sectional survey, Adelphi EoE Disease Specific Programme\u2122, collected physician and patient-reported data on clinical characteristics, HCRU, symptoms, comorbidities, and QOL of EoE patients with past\/current proton pump inhibitor use and ongoing dysphagia-related symptoms (September to December 2020) at study entry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Physicians provided clinical characteristics, symptom, comorbidity, and HCRU data for 412 patients (12\u201317\u00a0years: 8%; \u226518\u00a0years: 92%); and 161 of these patients (12\u201317\u00a0years: 6%; \u226518\u00a0years: 94%) provided symptom and QOL data. Of the 412 patients, 67% were male, with a mean (SD) age of 37.0 (15.3) years. Overall, 74% of patients were currently being treated with corticosteroids (12\u201317\u00a0years: 88%; \u226518\u00a0years: 73%); 25% of patients had a history of esophageal dilations (12\u201317\u00a0years: 19%; \u226518\u00a0years: 26%); and 30% of patients had EoE-related emergency room visit (12\u201317\u00a0years: 31%; \u226518\u00a0years: 30%) in the last year. Among the 161 patients, heartburn (69%) was the most commonly reported symptom; the greatest negative impacts on QOL were reported for dysphagia-related anxiety, social activities involving food, and maintaining friendships (EoE Impact Questionnaire scores [1\u20135, low to high impact]: 1.6\u20132.2 for both age groups).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>EoE patients continued to experience disease burden despite receiving treatment, highlighting the high unmet need for effective disease management in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/dote\/doaf024","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:18:14Z","timestamp":1742228294000},"source":"Crossref","is-referenced-by-count":6,"title":["Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis"],"prefix":"10.1093","volume":"38","author":[{"given":"Alain M","family":"Schoepfer","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne , Rue du Bugnon 44, 1005 Lausanne,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevie","family":"Olsen","sequence":"additional","affiliation":[{"name":"Adelphi Real World , Grimshaw Ln, Bollington, Macclesfield SK10 5JB,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Siddall","sequence":"additional","affiliation":[{"name":"Adelphi Real World , Grimshaw Ln, Bollington, Macclesfield SK10 5JB,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilish","family":"McCann","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhesh","family":"Kamat","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Borsos","sequence":"additional","affiliation":[{"name":"Sanofi , 450 Water St, Cambridge, MA 02141,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Khodzhayev","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Radwan","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pela","sequence":"additional","affiliation":[{"name":"Sanofi , 55 Corporate Dr, Bridgewater, NJ 08807,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby","family":"Jacob-Nara","sequence":"additional","affiliation":[{"name":"Sanofi , 55 Corporate Dr, Bridgewater, NJ 08807,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarette T","family":"Tilton","sequence":"additional","affiliation":[{"name":"Sanofi , 450 Water St, Cambridge, MA 02141,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B","family":"Thomas","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"key":"2025040619430906800_ref1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.anai.2020.03.020","article-title":"AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis","volume":"124","author":"Hirano","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025040619430906800_ref2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.cgh.2017.06.036","article-title":"Health-related quality of life and costs associated with eosinophilic esophagitis: a systematic review","volume":"16","author":"Mukkada","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025040619430906800_ref3","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1053\/j.gastro.2013.08.015","article-title":"Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner","volume":"145","author":"Schoepfer","year":"2013","journal-title":"Gastroenterology"},{"key":"2025040619430906800_ref4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/2050640617707095","article-title":"Determinant factors of quality of life in adult patients with eosinophilic esophagitis","volume":"6","author":"Lucendo","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"2025040619430906800_ref5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"2025040619430906800_ref6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.gtc.2014.02.002","article-title":"Epidemiology of eosinophilic esophagitis","volume":"43","author":"Dellon","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"2025040619430906800_ref7","doi-asserted-by":"crossref","first-page":"e14072","DOI":"10.1111\/nmo.14072","article-title":"Emerging incidence trends of eosinophilic esophagitis over 25 years: results of a nationwide register-based pathology cohort","volume":"33","author":"Rooij","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"2025040619430906800_ref8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/JAA.S274524","article-title":"Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions","volume":"15","author":"Franciosi","year":"2022","journal-title":"J Asthma Allergy"},{"key":"2025040619430906800_ref9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025040619430906800_ref10","doi-asserted-by":"crossref","first-page":"AB266","DOI":"10.1016\/j.jaci.2023.11.850","article-title":"Dupilumab improves histologic and endoscopic outcomes in children aged 1 to &lt;12 years with eosinophilic esophagitis (EoE): 52-week results from the phase 3 EoE KIDS trial","volume":"153","author":"Chehade","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2025040619430906800_ref11","author":"Dupixent","year":"2022"},{"key":"2025040619430906800_ref12","article-title":"News release","year":"2023"},{"key":"2025040619430906800_ref13","article-title":"Summary of product characteristics","author":"Dupixent","year":"2022"},{"key":"2025040619430906800_ref14","doi-asserted-by":"crossref","first-page":"AB91","DOI":"10.1016\/j.jaci.2020.12.347","article-title":"Dupilumab improves health-related quality of life (HRQoL) and reduces symptom burden in patients with eosinophilic esophagitis (EoE): results from part A of a randomized, placebo-controlled three-part phase 3 study","volume":"147","author":"Dellon","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2025040619430906800_ref15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/ajg.2009.657","article-title":"Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2025040619430906800_ref16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.anai.2020.03.021","article-title":"Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters","volume":"124","author":"Rank","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025040619430906800_ref17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11894-019-0729-y","article-title":"Allergies and eosinophilic esophagitis-current updates for the pediatric gastroenterologist","volume":"21","author":"Williamson","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"key":"2025040619430906800_ref18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12016-019-08733-0","article-title":"Allergic comorbidity in eosinophilic esophagitis: mechanistic relevance and clinical implications","volume":"57","author":"Capucilli","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025040619430906800_ref19","author":"Sanofi"},{"key":"2025040619430906800_ref20","doi-asserted-by":"crossref","first-page":"e061476","DOI":"10.1136\/bmjopen-2022-061476","article-title":"Metabolic adverse events associated with systemic corticosteroid therapy\u2014a systematic review and meta-analysis","volume":"12","author":"Kulkarni","year":"2022","journal-title":"BMJ Open"},{"key":"2025040619430906800_ref21","first-page":"17","article-title":"Mood and cognitive changes during systemic corticosteroid therapy","volume":"3","author":"Brown","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2025040619430906800_ref22","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/jcm11051454","article-title":"Formulations of topical steroids in eosinophilic esophagitis-current treatment and emerging possibilities","volume":"11","author":"G\u0142\u00f3wczewski","year":"2022","journal-title":"J Clin Med"},{"key":"2025040619430906800_ref23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.14309\/ajg.0000000000001850","article-title":"Poor adherence to medical and dietary treatments in adult patients with eosinophilic esophagitis","volume":"117","author":"Haasnoot","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2025040619430906800_ref24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/apt.13370","article-title":"Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity","volume":"42","author":"Safroneeva","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2025040619430906800_ref25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/MPG.0000000000002479","article-title":"Symptom burden and quality of life over time in pediatric eosinophilic esophagitis","volume":"69","author":"Klinnert","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025040619430906800_ref26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1053\/j.gastro.2014.08.028","article-title":"Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis","volume":"147","author":"Schoepfer","year":"2014","journal-title":"Gastroenterology"},{"key":"2025040619430906800_ref27","author":"Eohilia","year":"2024"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/2\/doaf024\/62874686\/doaf024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/2\/doaf024\/62874686\/doaf024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T15:43:56Z","timestamp":1743954236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doaf024\/8106811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doaf024","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,3]]},"article-number":"doaf024"}}